Board of Directors
Board of Directors
BioInvent’s Board of Directors is elected annually at the AGM for the period until the next AGM and shall, according to the Articles of Association, consist of no less than five and no more than nine members. The Articles of Association contain no special provisions regarding the election or dismissal of Board members.
The AGM 2026 discharged the Board members and the CEO Director from liability and re-elected the Board members Natalie Berner, Leonard Kruimer, Nanna Lüneborg and Bernd Seizinger and elected Kate Hermans and Scott Zinober as new Board members. Leonard Kruimer was re-elected Chairman of the Board. The Board of Directors consists of six directors elected by the General Meeting, as well as the employee representatives Elin Birgersson and Tomas Wall, and the employee deputy Anette Mårtensson.
All Board members elected by the General Meeting are independent in relation to the Company, senior executives, and major shareholders, except for Natalie Berner who is considered dependent in relation to major shareholders.
The AGM 2026 resolved that the Board’s fee shall amount to SEK 899,875 to the Chairman of the Board, SEK 575,000 to a vice chairman of the Board and SEK 488,750 to each of the other Board members, who are not employed by the company. In addition hereto, the AGM resolved on fees for committee work of (i) SEK 80,500 to the Chairman of the Audit Committee and SEK 57,500 to other members of the Audit Committee, (ii) SEK 40,250 to the Chairman of the Remuneration Committee and SEK 28,750 to other members of the Remuneration Committee, and (iii) SEK 80,500 to the Chairman of the R&D Committee and SEK 57,500 to other members of the R&D Committee.
The work of the Board of Directors is governed by rules of procedure which are revised and adopted by the Board of Directors
at least once a year. The rules of procedure primarily consist of directions for the Board of Directors work, instructions for the division of duties between the Board of Directors and the CEO and instructions for the financial reporting.
The Board of Directors conducts an annual structured evaluation of the Board of Directors and the CEO, and the result of this evaluation is shared with the Nomination Committee. The evaluation is conducted with the purpose to develop the Board of Directors’ procedures and efficiency. The evaluation takes the form of a questionnaire that the Board members answer, after which the responses are compiled and presented to the Board of Directors and the Nomination Committee along with the results of the evaluations carried out in the two preceding years.
Leonard Kruimer
Natalie Berner
Elin Birgersson
Leonard Kruimer
Chairman of the Board since 2018.
MBA, CPA. He served as a Board Member in BioInvent between 2016– 2017. He has held senior executive and board positions at European and US based biotech companies. He held senior executive positions at royal Boskalis NV, GE Capital and Continental Canada Company and has been a consultant with McKinsey and an auditor with Price Waterhouse New York. Born 1958.
Other board appointments: Board member in Zealand Pharma A/S, Basilea International AG and Pharming Group NV. Director in AI Global Investments (Netherlands) PCC Ltd.
Shareholding: 33,538
Natalie Berner
Member of the Board since 2022.
BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.
Other board appointments: Hansa Biopharma AB, Redx Pharma Plc and Sensorion SA.
Shareholding: -
Elin Birgersson
Member of the Board since 2023.
MSc in Chemical biology. Elin has worked at the university (KTH) and pharma and biotech industry since 2012 and has experience in antibody discovery and high-throughput analysis. Born 1985.
Other board appointments: -
Shareholding: 92 (affiliated holdings)
Conditional Employee Options: Option program 2023/2025: 2,549; Option program 2024/2026: 1,781; Option program 2025/2027: 1,283
Kate Hermans
Nanna Lüneborg
Bernd Seizinger
Kate Hermans
Member of the Board since 2026.
Master’s degree in international management from the Thunderbird School of Global Management and a bachelor's degree Magna Cum Laude in International Relations from Wheaton College. Completed Part I of the CEDEP International General Management Program at INSEAD. More than 35 years of leadership experience across large public enterprises and venture-backed biotechs, with multiple successful exits. Kate has held senior roles including Interim CEO and President of Ambrx Biopharma, as well as senior leadership positions at 83bar LLC, Radius Health, Bristol Myers Squibb, Pfizer/Wyeth, and Intel, working in the U.S., China, Africa, and globally. Kate is an active speaker across multiple industry forums. Born 1968.
Other board appointments: Chair of the Board of Clue by Biowink. Board member in Mid-Atlantic Diamond Ventures.
Shareholding: -
Nanna Lüneborg
Member of the Board since 2022.
PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and Novo Holdings. Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Capstan (acquired by Abbvie), Inversago Pharma (acquired by Novo Nordisk), Lava Therapeutics (LVTX), Numab (asset spin-out Yellow Jersey acquired by J&J), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.
Other board appointments: Board member in Maplight Therapeutics (MPLT), Sparrow Pharma, F2G and Noema Pharma, board observer in Numab Therapeutics.
Shareholding: -
Bernd Seizinger
Member of the Board since 2018.
Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.
Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB, and Aptose Inc. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as Pureos BioVentures
Shareholding: 66,000
Tomas Wall
Scott Zinober
Tomas Wall
Member of the Board since 2025.
Tomas has worked in IT Management since 2007 at companies in manufacturing, medical distribution, and pharma. Born in 1981.
Other board appointments: -
Shareholding: 1,240
Conditional Employee Options: Option program 2023/2025: 4,399. Option program 2024/2026: 2,749; Option program 2025/2027: 1,283
Scott Zinober
Member of the Board since 2026.
MBA from the MIT Sloan School of Management and a BA in Economics & Psychology from Williams College. More than 25 years of global public and private equity experience. He spent more than two decades at Viking Global Investors, where he held roles including Healthcare Analyst, Portfolio Manager, Senior Portfolio Manager, and Team Leader. He also served on Viking's Investment Steering Committee, Management Committee and the Viking Foundation Board. Earlier in his career, he focused on biotechnology investments at Putnam Investments. Born 1977.
Other board appointments: -
Shareholding: 50,000
Auditors
According to the Articles of Association, BioInvent shall appoint a registered auditing Company for a term of two years. The auditor attends at least one Board meeting a year not attended by the CEO and other members of the Company’s senior management.
The AGM 2026 elected KPMG AB to serve as the Company’s auditors for a two-year mandate. Linda Bengtsson, authorized public accountant, is principal auditor for the 2026 financial year.